Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
Retrieved on:
Friday, March 4, 2022
CHRS, ESCC, PFS, TP, Patient, PD-L1, OS, Death, Paclitaxel, European Society for Medical Oncology, Oncology, PD-1, Congress, HKEX, HR, Senior, European Society of Gynaecological Oncology, Health, CEO, Maintenance, Manuscript, SSE, FG, GLOBE, Cisplatin, Palladium, Pharmaceutical industry, Medical imaging, Cancer cell
REDWOOD CITY, Calif., and SHANGHAI, China, March 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced the online publication in Cancer Cell of Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center randomized phase 3 trial. The manuscript publication was accompanied by a Cancer Cell editorial preview entitled Jupiter-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma.
Key Points:
- The study results were first presented in a mini-oral session during the European Society for Medical Oncology (ESMO) Congress 2021.
- The robust results from the JUPITER-06 study add to the emerging body of clinical evidence of toripalimabs clinical activity across multiple tumor types.
- A statistically significant improvement in OS was detected in the toripalimab arm:
Median OS in the toripalimab and placebo arms were 17 vs. 11 months respectively. - Coherus and Junshi Biosciences plan to file additional toripalimab BLAs with the FDA over the next three years for multiple other cancer types.